Daily Management Review

Novartis to pay $ 9.7 billion for US biotech company The Medicines Co


Novartis buys The Medicines Co, a US-based biotechnology company, for about $ 9.7 billion. The Swiss pharmaceutical company aims to expand its portfolio of anti-cardiovascular drugs.

--Andrew- via flickr
--Andrew- via flickr
Novartis will pay $ 85 per share in cash, which is about 24% higher than The Medicines Co shares at $ 68.55 at the close of trading on Friday.

According to Novartis, the deal was approved by the boards of directors of both companies and will be funded from existing cash and short-term and long-term loans.

Novartis expects that the deal will beclosed in the first quarter of 2020. The firm believes that the Medicines Co’s drug Inclisiran, aimed to lower cholesterol, will begin to contribute to sales in 2021 and may become one of the largest in terms of sales of products in the portfolio of Novartis.

source: reuters.com

Science & Technology

Driverless Vehicle For Its Ride-Sharing Service Unveiled By GM’s Cruise

Amazon will allow customers to pay with palms instead of cards

Complete Computer System For Self Driving Cars Launched By Qualcomm

In A Lifetime We Could Accumulate 20Kg Micro-Plastic In Our Body

Creator Of The First 'Gene-Edited' Babies Of The World Gets 3 Year Jail Term In China

China to deploy giant Beidou global navigation system in 2020

VW Zwickau factory is getting ready for electric cars production

Airbus: Passenger hybrid aircraft to take off before 2035

Ocado To Introduce ‘Mini Robotic Warehouse’ With Standard Productivity

AB InBev’s Piled Up Alcohol Is ‘Too Good to Waste’

World Politics

World & Politics

UK adds Greenpeace, PETA to extremist organizations list

Indonesia, UAE sign nearly $23B deal

US to respond to Iran’s attacks on US bases in Iraq

Irish Passport issues hit record in anticipation of Brexit

Reporters Without Borders calls to release Julian Assange

IMF allocates Ecuador $ 500 mln more to support reforms

French pension reform chief to resign

Poland refuses to join EU 2050 climate deal